When was ArcDia founded?

ArcDia was founded in 2008 and raised its 1st funding round 4 years after it was founded.

Where is ArcDia located?

ArcDia is headquartered in Turku, Finland.

How many employees does ArcDia have?

As of May 31, 2026, the latest employee count at ArcDia is 20.

Is ArcDia a funded company?

ArcDia is a funded company, having raised a total of $5.92M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on May 12, 2012.

When was the latest funding round of ArcDia?

ArcDia's latest funding was a $***** Series A round on Sep 04, 2017, with participation from 1 investor.

Where does ArcDia rank among its competitors?

ArcDia ranks 57th amongst 346 active competitors, of which 82 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Daye, which secured $576K in Nov, 2025.

Who are the top competitors of ArcDia?

ArcDia's top competitors include Adaptive Biotechnologies, MeMed and HaystackAnalytics. Among them, Daye secured the most recent funding round in November, 2025.

ArcDia - 2026 Company Profile, Funding & Competitors

ArcDia is a series A company based in Turku (Finland), founded in 2008. It operates as a Point-of-care diagnostics for acute infectious diseases. ArcDia has raised $5.92M in funding. The company has 346 active competitors, including 82 funded and 51 that have exited. Its top competitors include companies like Adaptive Biotechnologies, MeMed and HaystackAnalytics.

Company Details

ArcDia International develops point-of-care diagnostic platforms for acute infectious diseases. Its flagship product, the mariPOC® test system, uses proprietary technology based on two-photon excitation of fluorescence detection, which allows separation-free analysis from small volumes of tissue samples. Currently, the mariPOC® system supports the Respitest (research use only) for detecting respiratory tract infections from nasopharyngeal samples, and the Pharyntest for differentiating between viral and bacterial throat infections from throat swab samples. It is also developing the Gastrotest for diagnosing acute gastroenteritis.

Key Metrics

Founded Year

2008

Location

Turku, Finland

Stage

Series A

Total Funding

$5.92M in 2 rounds

Latest Funding Round

Series A, Sep 04, 2017, $*****

Investors

Finnvera & 3 more

Ranked

57^th among 346 active competitors

Employee Count

20 as on May 31, 2026

Similar Companies

Adaptive Biotechnologies & 410 more

View ArcDia's full profile

ArcDia has raised a total funding of $5.92M over 2 rounds. Its first funding round was on May 12, 2012. Its latest funding round was a Series A round on Sep 04, 2017 for $*****. 1 investor participated in its latest round. ArcDia has 4 institutional investors.

Here is the list of recent funding rounds of ArcDia:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 04, 2017	8068953	Series A	5952667	8048378	9605416	4499008
May 12, 2012	3849686	Series A	7024278	9252908	3043524	Lifeline Ventures & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of ArcDia's funding rounds and investors

ArcDia's employee count trend

ArcDia has 20 employees as of May 26. Here is ArcDia's employee count trend over the years:

Uncover ArcDia's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ArcDia include Adaptive Biotechnologies, MeMed and HaystackAnalytics. Here is the list of Top 10 competitors of ArcDia, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Adaptive Biotechnologies 2009, Seattle (United States), Public	Provider of clinical diagnostics, and drug discovery for immune diseases	$419M	Viking Global Investors, Matrix & 21 others	77/100
2nd	MeMed 2009, Tirat Carmel (Israel), Series D	Provider of machine learning based diagnostic solutions for infectious diseases	$163M	La Maison Partners, Ping An & 23 others	69/100
3rd	HaystackAnalytics 2018, Mumbai (India), Seed	Provider of genomics technology for personalized clinical decisions	$17.3M	Sun Pharma, STRIVE & 31 others	67/100
4th	Daye 2018, London (United Kingdom), Series A	Manufacturer of period care products and provider of health tests	$19.2M	Salica Investments, Khosla Ventures & 24 others	60/100
5th	Huwel Life 2015, Hyderabad (India), Series A	Molecular diagnostic solutions and products for the healthcare industry	$5.74M	Bartronics, BIRAC & 3 others	59/100
6th	Oncimmune 2006, Cambridge (United States), Acquired	Immunodiagnostics company developing biomarker platforms for cancer and immune diseases	-	IPF Partners, Balderton Capital & 9 others	58/100
7th	Karius 2014, Redwood City (United States), Series C	Provider of diagnostics for identifying infectious diseases using microbial DNA	$315M	Khosla Ventures, Gilde Healthcare & 16 others	58/100
8th	Clear Labs 2014, Menlo Park (United States), Series D	Provider of food safety technologies for the identification of pathogens	$171M	Menlo Ventures, Google Ventures & 26 others	57/100
9th	Seegene Technologies 2000, Seoul (South Korea), Public	Provider of advanced molecular diagnostics solutions	-	IMM Investment, HHS & 3 others	57/100
10th	Quantamatrix 2010, Seoul (South Korea), Public	Multiplexed platform for disease daignosis	$198K	Treatment Action Group, Partners Investment ... & 6 others	55/100
57th	ArcDia 2008, Turku (Finland), Series A	Point-of-care diagnostics for acute infectious diseases	$5.92M	Finnvera, Lifeline Ventures & 2 others	38/100